Shiba Inu (SHIB) burned 673,379,117 tokens over a 30-day period ending Oct. 23, a rate that would take about 714 years to burn 1% of its circulating supply if it continues. The circulating supply was 585.5 trillion SHIB, with 1% equaling about 5.85 trillion tokens. Daily burns averaged 22.4 million SHIB, with 2.47 million burned in the last 24 hours. So far, 41.08% of the original one quadrillion SHIB tokens have been burned. This slow burn rate highlights the challenge of significantly reducing SHIB supply through token burns alone.
Shiba Inu token burn pace is the subject, with Pluang market data as of Oct 23, 2026 22:21 WIB. For readers following cryptocurrency markets, 36 of 50 major cryptocurrencies rose and 12 fell today on Pluang. Notable movers include BAT at Rp3.136 with a 1-day change of +3.25%, LUNC at Rp0,837 with +2.68%, and BNB at Rp13.518.040 with +2.63%. BAT's Pluang order activity showed 66% Buy, and its typical hold time is 93 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
